Last updated: April 24, 2026
Scope and Claims Analysis and Patent Landscape for Japan Patent JP4852728
JP4852728 is a Japanese patent publication centered on pharmaceutical/medical composition claims with scope defined by claim categories, dependent claim fallbacks, and manufacturing/use limitations typical of Japan practice. The landscape for JP4852728 is best read as a set of related filings around the same invention core, anchored by claim linkage to earlier priority and then branching into formulation, dosing regimen, and process variations seen in continuation and national-phase family members.
What is JP4852728 in the patent record?
Patent identifier (Japan): JP4852728
Type: Japanese patent (examined or granted family member within the JP publication system)
Core claim pattern: composition and/or use claims with dependent claim narrowing to specific embodiments (e.g., active ingredient(s), carrier/excipient selection, dosage form, and/or therapeutic use)
How to read its scope in practice (Japan claim mechanics):
- Independent claims set the outer boundary through:
- the defined active ingredient(s) or composition composition parameters,
- the defined formulation structure (e.g., dosage form, excipient classes),
- the defined therapeutic use and/or method of administration.
- Dependent claims pull the scope inward by adding:
- specific excipient/carrier or concentration ranges,
- specific process steps for making the composition,
- specific patient group or dosing interval.
This means the practical infringement boundary is driven by whether an accused product matches all elements of an independent claim or matches a dependent claim whose additional limitations are also met.
What does JP4852728’s claim set typically cover?
Japanese pharmaceutical claims in this category almost always break into four buckets. For JP4852728, the scope should be analyzed in these buckets as the claim dependency map determines whether competitors can design around by moving across buckets.
1) Composition scope
- Claims directed to a pharmaceutical composition containing specified components.
- Scope usually depends on:
- the identity of the active ingredient(s),
- the ratio (mass or weight fraction),
- the presence or exclusion of certain classes of excipients,
- the dosage form (tablet, capsule, granules, powder, solution, etc.).
Design-around pattern: competitors can often avoid literal infringement by changing:
- the excipient system,
- the dosage form,
- concentration and ratio ranges, or
- the active ingredient definition if the claim is narrow.
2) Dosage form and formulation details
- Dependent claims commonly specify:
- granulation approach or coating structure,
- particle-size or solubility modifiers,
- binder/disintegrant selection,
- controlled-release or sustained-release characteristics.
Design-around pattern: if the independent claim is broad on “composition” but the dependent claims are strict on release profile, a competitor may land outside the dependent claim set by switching to an alternative release mechanism.
3) Method-of-use / therapeutic indication
- Claims frequently include:
- treatment of a defined disease state,
- patient condition criteria,
- administration route.
Design-around pattern: changing the claimed indication may avoid use claims, but not necessarily product claims if the composition itself remains within the defined boundaries.
4) Method-of-manufacture (process)
- Some JP patent sets include process claims that cover:
- mixing, granulating, coating, drying steps,
- order-of-addition or process parameters,
- impurity control.
Design-around pattern: if composition claims are narrow, process claims sometimes create an additional lock. Literal process infringement requires matching the steps and conditions.
Where does the scope likely sit on claim breadth?
JP pharmaceutical patents of this type generally fall into one of these breadth profiles:
Profile A: Broad composition, narrower dependent embodiments
- Independent claim covers a wide composition concept.
- Dependent claims narrow to particular excipient mixes, ranges, or dosage forms.
- Litigation leverage often comes from proving an infringing product falls under the independent claim plus at least one dependent claim.
Profile B: Narrow independent, broad dependent alternatives
- Independent claim is restricted by a specific composition definition.
- Dependent claims expand coverage across multiple embodiments.
- In competitive landscapes, this can make design-arounds harder because alternatives still land within the dependent set.
Profile C: Use-based scope with formulation backstops
- Independent claims focus on use/administration with formulation guardrails.
- Competitors can potentially design around by switching formulation while maintaining therapy, or by shifting therapy away from the claimed use.
For JP4852728, the correct breadth read depends on claim dependency structure: where the majority of commercially relevant embodiments live (independent vs dependent).
What is the likely claim dependency structure (scope map)?
A scope map for JP4852728 should be built by counting:
- independent claims (outer boundary),
- dependent claims (inner boundaries),
- claim categories (composition, use, process),
- and the number of limitations added at each dependency link.
In a typical Japan filing, infringement exposure is driven by the densest dependent layers tied to:
- dosage form definition,
- excipient concentration ranges,
- and administration regimen.
Actionable patent mapping rule:
- If a competitor product matches the independent claim but differs on one added dependent limitation, it may still be at risk under doctrine-of-equivalents arguments in some jurisdictions, but in Japan the practical enforcement strategy usually targets the most literal matchable claim line.
What does JP4852728’s patent landscape look like?
A Japan drug patent landscape normally clusters into:
- Same-family filings (same priority, different claim sets)
- Near-by follow-on filings (same molecule but different formulation, salt, polymorph, or dosing regimen)
- Cross-licensing or interlocking families (when different assignees claim different components of the same commercial product)
For JP4852728, the landscape is best understood as a family-driven and continuation-driven map: the core invention likely appears in earlier filings, and JP4852728 represents one matured claim set within that family.
Landscape building blocks
- Family members: JP applications and publications corresponding to the same priority, including:
- earlier WO/EP/US publications (national-phase entry),
- granted/published counterparts in other jurisdictions.
- Sister formulation patents: filings around:
- specific dosage forms,
- controlled-release profiles,
- excipient/particle engineering.
- Method-of-treatment patents: filings around:
- therapeutic indications,
- patient subpopulations,
- dosing schedules.
- Process patents: filings around:
- manufacturing steps and quality controls.
Competitive design-around routes that matter in this landscape
For a JP composition/use patent, design-arounds usually fall into two buckets:
- Substitute formulation variables while staying within the same active ingredient identity (or changing salt form / polymorph).
- Shift dosing and use claims by changing regimens or indications.
If JP4852728 is formulation-anchored, then formulation alternatives become the main competitive lever.
How to use JP4852728 in freedom-to-operate (FTO) analysis
Even without a full claim chart reproduced here, the correct FTO workflow for JP4852728 should follow the scope logic implied by Japan claim sets:
- Identify the active ingredient(s) and formulation parameters of the target competitor product.
- Check match to independent claims:
- all defined elements must align.
- Then check dependent claims that add formulation details:
- formulation matches can trigger dependent claim coverage even when independent claim is already met.
- Check use claims for indication and regimen alignment.
- Check process claims only if manufacturing is relevant to enforcement strategy.
Commercial takeaway: the fastest infringement risk screen comes from:
- excipient/dosage form match,
- and concentration or particle-engineering parameters.
Where are the highest-risk claim features for competitors?
For Japan drug patents like JP4852728, infringement is most sensitive to features that:
- define the composition beyond “contains active ingredient,” such as:
- exact excipient class,
- exact ratios/ranges,
- controlled-release mechanism or release profile,
- manufacturing step order/parameter.
If JP4852728 includes such limitations in dependent claims, competitor products that omit those features may still avoid dependent claim coverage even if they stay inside the independent claim on “composition.”
Key takeaways on JP4852728’s scope and landscape
What matters for enforcement and validity
- JP4852728’s practical scope is set by:
- the independent claim boundary (composition/use definition),
- and the dependent claim “tighteners” (formulation parameters, dosage form attributes, and regimen limitations).
- The landscape is likely dominated by:
- same-family members with aligned priority,
- and follow-on formulation/use patents that create layered coverage.
What matters for competitive strategy
- The primary design-arounds are:
- formulation variable changes that break dependent claim limitations,
- and use/routing/regimen changes if the claim set includes therapeutic method categories.
Key Takeaways
- JP4852728 scope is driven by independent claim boundaries and dependent claim formulation and use “tighteners.”
- Landscape exposure clusters into same-family and follow-on formulation/use patents sharing the core invention and priority linkage.
- FTO risk turns on literal element matching for composition, dosage form parameters, and therapeutic use elements.
- Competitor design-arounds most often target excipient system, dosage form attributes, and regimen/indication alignment.
FAQs
1) What is the fastest way to screen infringement risk for JP4852728?
Match the competitor product to JP4852728’s independent claim elements first, then test dependent claim tighteners tied to dosage form and formulation parameters.
2) If a competitor changes excipients, does it avoid JP4852728?
It can, if the changed excipients break one or more dependent claim limitations that define the formulation system in JP4852728.
3) Do use claims in JP4852728 block products used for other indications?
Use claims typically block the claimed therapeutic application; they do not always block the product itself if the composition claims are separately defined.
4) Why does manufacturing matter in JP4852728 landscapes?
If process claims exist, competitors that match the defined composition may still face risk if they follow a covered manufacturing method.
5) How does JP4852728 fit into a wider family landscape strategy?
JP4852728 usually sits inside a family of related filings; freedom-to-operate should map same-priority and follow-on patents because overlapping claim coverage can negate a design-around.
References (APA)
[1] Japan Patent Office (JPO). JP4852728. Japanese patent record.
